About ENB Therapeutics

Website
Website
Employees
Employees
1-10 employees View all
Industry
Industry
Pharmaceuticals
Location
Location
166 Fifth Ave, 2nd Flr, New York, NY 10010, US
Description
Information
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

ENB Therapeutics Alternatives

Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
Pharmaceuticals
Industry
Pharmaceuticals
Industry
pharmaceuticals
Industry
pharmaceuticals
Industry
Pharmaceuticals

Frequently Asked Questions about ENB Therapeutics

What is ENB Therapeutics email format?

The widely used ENB Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.


What is ENB Therapeutics customer service number?

To contact ENB Therapeutics customer service number in your country click here to find.


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more